Tearing down the walls: FDA approves next generation sequencing (NGS) assays for actionable cancer genomic aberrations

Abstract excerpt

The United States Food and Drug Administration (FDA) recently approved the clinical use of two comprehensive 'mid-size' Next Generation Sequencing (NGS) panels calling actionable genomic aberrations in cancer. This is the first endorsement, by a regulatory body, of a new standard of care in oncology. Herein, we argue that besides its many practice-changing implications, this approval tears down the conceptual...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cancer Genomics and Diagnostics
• Share to Genomics and Rare Diseases
• Share to PARP inhibition in cancer therapy